Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie logo
$285.66 +0.47 (+0.16%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$285.27 -0.39 (-0.14%)
As of 10/23/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
6
Buy
24

Based on 30 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 6 have given a hold rating, 23 have given a buy rating, and 1 has given a strong buy rating for ABBV.

Consensus Price Target

$279.86
-2.03% Downside
According to the 30 analysts' twelve-month price targets for AbbVie, the average price target is $279.86. The highest price target for ABBV is $325.00, while the lowest price target for ABBV is $225.00. The average price target represents a forecasted downside of -2.03% from the current price of $285.66.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABBV Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
1 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
23 Buy rating(s)
23 Buy rating(s)
18 Buy rating(s)
16 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$279.86$272.66$265.96$236.19
Forecasted Upside-2.03% Downside3.10% Upside3.49% Upside3.57% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieHealthcare CompaniesBroader Market
Consensus Rating Score
2.83
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside-2.03% Downside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent ABBV News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Asad Haider
5 of 5 stars
Boost TargetNeutral$258.00 ➝ $294.00+3.31%
10/21/2026
Barclays PLC logo
Barclays
3 of 5 stars
Emily Field
Not Rated
Boost TargetOverweight$300.00 ➝ $325.00+12.59%
10/13/2026
Trung Huynh
Not Rated
Reiterated RatingOutperform$280.00+0.58%
10/9/2026Reiterated RatingBuy$288.00+4.85%
10/8/2026 UpgradeBuy (B-) ➝ Buy (B)
10/8/2026Boost TargetOverweight$285.00 ➝ $300.00+10.21%
10/8/2026Boost TargetOverweight$285.00 ➝ $290.00+6.87%
10/7/2026Boost TargetOverweight$296.00 ➝ $310.00+14.10%
10/6/2026Boost TargetOutperform$280.00 ➝ $320.00+21.56%
10/6/2026Boost TargetNeutral$260.00 ➝ $275.00+4.47%
9/10/2026Boost TargetBuy$300.00 ➝ $315.00+25.48%
9/8/2026Reiterated RatingBuy
8/20/2026Boost TargetOverweight$298.00 ➝ $303.00+14.07%
8/17/2026Boost TargetOverweight$295.00 ➝ $300.00+20.38%
8/13/2026UpgradePeer Perform ➝ Outperform$235.00 ➝ $300.00+20.42%
8/11/2026Boost TargetNeutral$218.00 ➝ $247.00-1.15%
8/5/2026 Boost TargetOutperform$245.00 ➝ $279.00+4.74%
8/5/2026 UpgradeHold ➝ Buy
8/4/2026 Boost TargetBuy$284.00 ➝ $285.00+6.99%
8/4/2026 Boost Target$250.00 ➝ $270.00+1.36%
8/3/2026Boost TargetBuy$282.00 ➝ $290.00+15.39%
8/3/2026 Boost TargetNeutral$244.00 ➝ $258.00-3.15%
7/15/2026Boost TargetNeutral$230.00 ➝ $260.00+6.23%
7/13/2026Boost TargetOutperform$258.00 ➝ $300.00+20.97%
6/23/2026 Reiterated RatingMarket Perform$203.00 ➝ $225.00-4.00%
5/15/2026 Set TargetOutperform$236.00 ➝ $235.00+10.71%
5/5/2026 Lower TargetOutperform$244.00 ➝ $237.00-11.09%
4/30/2026 UpgradeHold ➝ Strong-Buy
3/9/2026 Reiterated RatingOutperform
1/20/2026Set TargetBuy$270.00 ➝ $275.00+28.28%
11/3/2025Set TargetOutperform$250.00 ➝ $256.00+17.36%
10/3/2025 Boost TargetBuy$250.00 ➝ $280.00+5.12%
9/15/2025 Boost TargetHold$173.00 ➝ $204.00-23.41%
2/3/2025Boost TargetBuy$211.00 ➝ $217.00+14.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:26 PM ET.


Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie received FDA approval on October 23, 2026, for a subcutaneous induction regimen for SKYRIZI in Crohn's disease, a significant expansion that supports early symptomatic control and strengthens the company's immunology portfolio against competitors.
  • The stock is currently trading at $285.66, which is near its 52-week high of $291.40, reflecting strong recent momentum and a consensus rating of Moderate Buy with a price target of $278.07, indicating analyst confidence in the company's trajectory.
  • AbbVie reported Q2 2026 revenue of $16.99 billion, beating estimates of $16.80 billion and growing 10.2% year-over-year, demonstrating robust commercial execution and demand for its key products like Skyrizi and Rinvoq.
  • The company offers a dividend yield of 2.43% with a recent quarterly payout of $1.73 per share, providing a steady income stream for investors, supported by a long history of dividend increases and a payout ratio that remains manageable relative to its earnings power.
  • AbbVie's lutikizumab met its primary endpoint in the Phase 3 INTREPID trial for hidradenitis suppurativa, adding a new potential revenue driver in the immunology space and diversifying the company's pipeline beyond its core franchises.

AbbVie
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AbbVie for these reasons:

  • Analysts have recently lowered earnings forecasts, with Erste Group Bank reducing its FY2026 EPS estimate to $13.90 from $14.00, and the consensus estimate for full-year earnings has dropped to $13.94, signaling potential pressure on profitability.
  • The stock trades at a P/E ratio of 80.69, which is significantly high and suggests that the market is pricing in substantial future growth, leaving little room for error if earnings disappoint or if the company faces patent cliff challenges.
  • AbbVie halted an early-stage liver cancer combination trial, a setback in its oncology pipeline that may limit near-term growth opportunities in that therapeutic area and raise questions about the success rate of its newer drug candidates.
  • Despite meeting trial endpoints, the efficacy of lutikizumab in the INTREPID trial was characterized by some analysts as below expectations, with the advantage over placebo viewed as underwhelming, which could limit its commercial impact and competitive positioning.
  • Institutional investors have been reducing their stakes, with funds like Vest Financial LLC and Investment House LLC significantly cutting their positions in the third quarter, indicating a lack of confidence from large holders in the stock's near-term performance.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $279.86, with a high forecast of $325.00 and a low forecast of $225.00.

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 6 hold ratings, 23 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted downside of -2.03% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 4 upgrades by analysts.

Analysts like AbbVie more than other "healthcare" companies. The consensus rating for AbbVie is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABBV compares to other companies.


MarketBeat monitors more than a dozen sources for AbbVie analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners